Sangamo BioSciences Inc (SGMO)

4.29
0.05 1.15
NASDAQ : Health Care
Prev Close 4.34
Open 4.31
Day Low/High 4.19 / 4.44
52 Wk Low/High 4.08 / 9.91
Volume 866.05K
Avg Volume 882.60K
Exchange NASDAQ
Shares Outstanding 70.62M
Market Cap 302.25M
EPS -0.60
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Sangamo BioSciences Announces New Gene Therapy Clinical Development Program For Treatment Of Hemophilia A

Sangamo BioSciences Announces New Gene Therapy Clinical Development Program For Treatment Of Hemophilia A

Scientists Present Preclinical Data Demonstrating High Levels of Factor VIII Protein Expression from Proprietary Therapeutic AAV cDNA Construct at World Federation of Hemophilia 2016 World Congress

First Week of SGMO February 2017 Options Trading

First Week of SGMO February 2017 Options Trading

Investors in Sangamo BioSciences Inc saw new options begin trading this week, for the February 2017 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 240 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Sangamo BioSciences Announces FDA Clearance Of Investigational New Drug Application For ZFN-Mediated Genome Editing Treatment Of MPS II

Sangamo BioSciences Announces FDA Clearance Of Investigational New Drug Application For ZFN-Mediated Genome Editing Treatment Of MPS II

Company Advances Third In Vivo Protein Replacement Platform™ (IVPRP) Program into Clinical Development

Sangamo BioSciences Announces Retirement Of Edward Lanphier As President And CEO; Sandy Macrae Named As Successor

Sangamo BioSciences Announces Retirement Of Edward Lanphier As President And CEO; Sandy Macrae Named As Successor

Leadership Transition Underlines Evolution from a Platform Company to a Therapeutic Product Company

Sangamo BioSciences Presents Recent Developments From Research And ZFP Therapeutic® Programs In Multiple Presentations At Annual Meeting Of The American Society Of Gene And Cell Therapy

Sangamo BioSciences Presents Recent Developments From Research And ZFP Therapeutic® Programs In Multiple Presentations At Annual Meeting Of The American Society Of Gene And Cell Therapy

New Histologic Data Demonstrate Disease Correction in Tissues after ZFP Therapeutic Treatment in Mouse Model of MPS I

7 Stocks Under $10 to Trade for Big Profits

7 Stocks Under $10 to Trade for Big Profits

When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

Today's Weak On High Volume Stock: Sangamo BioSciences (SGMO)

Today's Weak On High Volume Stock: Sangamo BioSciences (SGMO)

Trade-Ideas LLC identified Sangamo BioSciences (SGMO) as a weak on high relative volume candidate

Commit To Buy Sangamo BioSciences At $5, Earn 23% Using Options

Commit To Buy Sangamo BioSciences At $5, Earn 23% Using Options

Investors considering a purchase of Sangamo BioSciences Inc shares, but tentative about paying the going market price of $6.91/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the January 2018 put at the $5 strike, which has a bid at the time of this writing of $1.15.

These 5 Biotech Stocks Under $10 Are About to Break Out

These 5 Biotech Stocks Under $10 Are About to Break Out

When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

7 Stocks Under $10 to Trade for Breakout Gains

7 Stocks Under $10 to Trade for Breakout Gains

These stocks trading for less than $10 a share are within range of triggering big breakout trades.

Sangamo BioSciences (SGMO) Flagged As Strong On High Volume

Sangamo BioSciences (SGMO) Flagged As Strong On High Volume

Trade-Ideas LLC identified Sangamo BioSciences (SGMO) as a strong on high relative volume candidate

Sangamo BioSciences Presents New Data From In Vivo Protein Replacement Platform Programs For MPS I And MPS II At The 12th Annual WORLDSymposium™ Meeting

Sangamo BioSciences Presents New Data From In Vivo Protein Replacement Platform Programs For MPS I And MPS II At The 12th Annual WORLDSymposium™ Meeting

IVPRP Approach Permits Therapeutic Enzymes for Lysosomal Storage Disorders to Cross the Blood Brain Barrier Improving Cognitive Symptoms of Disease

Sangamo BioSciences Presents Phase 2 Immunological Data From SB-728-T ZFP Therapeutic® HIV Program At CROI 2016

Sangamo BioSciences Presents Phase 2 Immunological Data From SB-728-T ZFP Therapeutic® HIV Program At CROI 2016

Subjects from SB-728-1101 Cohort 3* Remain Off Antiretroviral Therapy for Over a Year

Sangamo BioSciences Announces FDA Clearance Of Investigational New Drug Application For ZFN-Mediated Genome Editing Treatment Of MPS I

Sangamo BioSciences Announces FDA Clearance Of Investigational New Drug Application For ZFN-Mediated Genome Editing Treatment Of MPS I

Program is the Second of the Company's In Vivo Protein Replacement Platform™ Programs to Enter Clinical Development

Sangamo BioSciences Becomes Oversold (SGMO)

Sangamo BioSciences Becomes Oversold (SGMO)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Strong On High Volume: Sangamo BioSciences (SGMO)

Strong On High Volume: Sangamo BioSciences (SGMO)

Trade-Ideas LLC identified Sangamo BioSciences (SGMO) as a strong on high relative volume candidate

Oversold Conditions For Sangamo BioSciences (SGMO)

Oversold Conditions For Sangamo BioSciences (SGMO)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.